Hepion Pharmaceuticals Inc. (NASDAQ:HEPA) has a beta of 1.14. The stock’s Relative Strength Index (RSI) is 41.34, with weekly volatility at 5.66% and ATR at 0.16. The HEPA stock’s 52-week price range has touched low of $1.26 and a $4.83 high. Its shares traded lower over the last trading session, losing -4.71% on 04/07/21. The shares fell to a low of $1.82 before closing at $1.82. Intraday shares traded counted 2.08 million, which was 67.34% higher than its 30-day average trading volume of 6.38M. HEPA’s previous close was $1.91 while the outstanding shares total 76.23M.
Investors have identified the Biotechnology company Hepion Pharmaceuticals Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $128.31 million, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Hepion Pharmaceuticals Inc. (HEPA) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. In terms of their assets, the company currently has 42.63 million total, with 4.66 million as their total liabilities.
Having a look at the company’s valuation, the company is expected to record -0.57 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on HEPA sounds very interesting.
Is the stock of HEPA attractive?
In related news, Chief Financial Officer, Cavan John T bought 10,000 shares of the company’s stock in a transaction that recorded on Feb 18. The purchase was performed at an average price of 2.00, for a total value of 20,000. As the purchase deal closes, the CEO and Director, Foster Robert T now bought 20,000 shares of the company’s stock, valued at 40,000. Also, Director, Wijngaard Peter bought 10,000 shares of the company’s stock in a deal that was recorded on Feb 16. The shares were cost at an average price of 2.20 per share, with a total market value of 22,000. Following this completion of disposal, the Director, Wijngaard Peter now holds 20,000 shares of the company’s stock, valued at 38,200. In the last 6 months, insiders have changed their ownership in shares of company stock by 0.10%.